EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Facilitators and barriers to decentralized Long COVID platform clinical trials using repurposed drugs

Marco Schito, Stacey Coe, Jaime Seltzer, Hannah E Davis, Vidula Sukhatme, Theodore W Johnson Ii, Judy Stone, Alexander D Truong, Linda N Geng, Tiffany A Walker

Frontiers in Public Health · 2026

DOI: 10.3389/fpubh.2026.1822376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Public Health, 2026. Verfasst von Marco Schito und 9 weiteren Autor:innen. Beteiligte Einrichtung: CURE Drug Repurposing Collaboratory, Critical Path Institute, Tucson, AZ, United States. Hauptthemen laut MEDLINE: Drug Repositioning, Clinical Trials as Topic, COVID-19 Drug Treatment. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FDA HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long COVID is an emerging chronic condition that results in substantial impairments in quality of life, physical function, and ability to maintain gainful employment. There are no FDA-approved treatments for Long COVID, and recent institution-based clinical trials have not yielded effective treatments. Current standard of care involves trial-and-error drug repurposing that warrants evaluation in rigorous clinical trials. Here we describe potential advantages of decentralized repurposing drug trials as an alternative or complementary approach to institution-based trials. Additionally, we describe lessons learned when launching a local feasibility pilot trial that may inform the design of future decentralized trials in the Long COVID field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug RepositioningClinical Trials as TopicCOVID-19 Drug TreatmentHumansPost-Acute COVID-19 SyndromeCOVID-19SARS-CoV-2Research Design

Stichwörter der Autor:innen

Long COVIDclinical trial designdecentralized clinical trialspatient reported outcome measuresrepurposed drugs

Autor:innen und Institutionen

  • CURE Drug Repurposing Collaboratory, Critical Path Institute, Tucson, AZ, United States.
  • Myalgic Encephalomyelitis Action Network, Santa Monica, CA, United States.
  • Stanford University School of Medicine, Stanford, CA, United States.
  • Patient Led Research Collaborative, New York, NY, United States.
  • Global Cures, Inc., Newton, MA, United States.
  • Emory University School of Medicine, Atlanta, GA, United States.

Förderung

  • FDA HHS

Zitieren

APA

Schito, M., Coe, S., Seltzer, J., Davis, H. E., Sukhatme, V., Johnson Ii, T. W., Stone, J., Truong, A. D., Geng, L. N., & Walker, T. A. (2026). Facilitators and barriers to decentralized Long COVID platform clinical trials using repurposed drugs. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2026.1822376

Vancouver

Schito M, Coe S, Seltzer J, Davis HE, Sukhatme V, Johnson Ii TW, et al. Facilitators and barriers to decentralized Long COVID platform clinical trials using repurposed drugs. Frontiers in Public Health. 2026. doi:10.3389/fpubh.2026.1822376

BibTeX
@article{Schito2026,
  author = {Schito, Marco and Coe, Stacey and Seltzer, Jaime and Davis, Hannah E and Sukhatme, Vidula and Johnson Ii, Theodore W and Stone, Judy and Truong, Alexander D and Geng, Linda N and Walker, Tiffany A},
  title = {Facilitators and barriers to decentralized Long COVID platform clinical trials using repurposed drugs},
  journal = {Frontiers in Public Health},
  year = {2026},
  doi = {10.3389/fpubh.2026.1822376}
}
Kostenlos starten →